Barinthus Biotherapeutics plc. (BRNS) Form 8-K — Sep 9, 2026
Barinthus Biotherapeutics completed its previously announced merger on September 9, 2026, when the court-sanctioned UK scheme of arrangement became effective and Beacon Topco, Inc. acquired the company's entire issued share capital, making Barinthus a wholly-owned subsidiary of Topco under the Merger Agreement with Clywedog Therapeutics. Under the transaction, holders received 0.111 shares of Topco common stock for each Barinthus share or ADS, with outstanding Company options and RSUs converted into Topco equity awards on the same terms, and the April 2021 deposit agreement with Bank of New York Mellon terminated.
Key figures
- Exchange Ratio
- 0.111 shares of Topco common stock per Company Share (and per Company ADS)
- Court Sanction Date
- 2026-09-01
- Topco Share Par Value
- USD 0.0001 per share
- Scheme Effective Date
- 2026-09-09
- Company Share Nominal Value
- GBP 0.000025 per share
- Original Merger Agreement Date
- 2025-09-29
- Merger Agreement Amendment Date
- 2026-02-22
Price after filing
Close on the filing date to close N calendar days later (from $0.74). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.